Is Ironwood Pharmaceuticals Stock a Good Investment?
Ironwood Pharmaceuticals Investment Advice | IRWD |
- Examine Ironwood Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Ironwood Pharmaceuticals' leadership team and their track record. Good management can help Ironwood Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Ironwood Pharmaceuticals' business and its evolving consumer preferences.
- Compare Ironwood Pharmaceuticals' performance and market position to its competitors. Analyze how Ironwood Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Ironwood Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Ironwood Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Ironwood Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Ironwood Pharmaceuticals is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Ironwood Pharmaceuticals Stock
Researching Ironwood Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 98.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.01. Ironwood Pharmaceuticals last dividend was issued on the 2nd of April 1970. The entity had 1194:1000 split on the 2nd of April 2019.
To determine if Ironwood Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Ironwood Pharmaceuticals' research are outlined below:
| Ironwood Pharmaceuticals generated a negative expected return over the last 90 days | |
| Ironwood Pharmaceuticals has high historical volatility and very poor performance | |
| Ironwood Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 442.74 M. Net Loss for the year was (1 B) with profit before overhead, payroll, taxes, and interest of 366.33 M. | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Ironwood Pharmaceuticals Stock Surges Amid Strong Financials and Buy Ratings |
Ironwood Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Ironwood Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Ironwood Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 15th of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 15th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Ironwood Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Ironwood Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2020-05-06 | 2020-03-31 | 0.05 | 0.04 | -0.01 | 20 | ||
2011-05-12 | 2011-03-31 | -0.17 | -0.19 | -0.02 | 11 | ||
2011-03-03 | 2010-12-31 | -0.14 | -0.12 | 0.02 | 14 | ||
2021-05-06 | 2021-03-31 | 0.21 | 0.24 | 0.03 | 14 | ||
2018-05-01 | 2018-03-31 | -0.23 | -0.27 | -0.04 | 17 | ||
2018-02-15 | 2017-12-31 | -0.18 | -0.14 | 0.04 | 22 | ||
2017-11-02 | 2017-09-30 | -0.22 | -0.18 | 0.04 | 18 | ||
2016-05-09 | 2016-03-31 | -0.13 | -0.09 | 0.04 | 30 |
Know Ironwood Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Ironwood Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Ironwood Pharmaceuticals backward and forwards among themselves. Ironwood Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Ironwood Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Kynam Capital Management, Lp | 2024-09-30 | 3.7 M | Geode Capital Management, Llc | 2024-09-30 | 3.3 M | Charles Schwab Investment Management Inc | 2024-09-30 | 1.9 M | Jpmorgan Chase & Co | 2024-06-30 | 1.9 M | Ubs Group Ag | 2024-06-30 | 1.8 M | Amvescap Plc. | 2024-06-30 | 1.7 M | Goldman Sachs Group Inc | 2024-06-30 | 1.6 M | Northern Trust Corp | 2024-09-30 | 1.5 M | Jupiter Asset Management Limited | 2024-09-30 | 1.4 M | Blackrock Inc | 2024-06-30 | 22.9 M | Vanguard Group Inc | 2024-09-30 | 22 M |
Ironwood Pharmaceuticals' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 587.3 M.Market Cap |
|
Ironwood Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.14) | (2.04) | |
| Return On Capital Employed | 1.07 | 1.13 | |
| Return On Assets | (2.13) | (2.02) | |
| Return On Equity | 2.89 | 3.04 |
Determining Ironwood Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Ironwood Pharmaceuticals is a good buy. For example, gross profit margin measures Ironwood Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Ironwood Pharmaceuticals' profitability and make more informed investment decisions.
Ironwood Pharmaceuticals' Earnings Breakdown by Geography
Please note, the presentation of Ironwood Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Ironwood Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Ironwood Pharmaceuticals' management manipulating its earnings.
Evaluate Ironwood Pharmaceuticals' management efficiency
Ironwood Pharmaceuticals has return on total asset (ROA) of 0.1305 % which means that it generated a profit of $0.1305 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.7472) %, meaning that it created substantial loss on money invested by shareholders. Ironwood Pharmaceuticals' management efficiency ratios could be used to measure how well Ironwood Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At present, Ironwood Pharmaceuticals' Return On Equity is projected to slightly grow based on the last few years of reporting. At present, Ironwood Pharmaceuticals' Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 356.5 M, whereas Non Currrent Assets Other are forecasted to decline to about 3.4 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (2.23) | (2.34) | |
| Tangible Book Value Per Share | (2.25) | (2.36) | |
| Enterprise Value Over EBITDA | (2.60) | (2.73) | |
| Price Book Value Ratio | (5.13) | (4.88) | |
| Enterprise Value Multiple | (2.60) | (2.73) | |
| Price Fair Value | (5.13) | (4.88) | |
| Enterprise Value | 2.2 B | 2.4 B |
Effective management at Ironwood Pharmaceuticals has been a driving force behind its market achievements. We assess the correlation between management practices and financial success to determine the stock's value.
Beta 0.475 |
Basic technical analysis of Ironwood Stock
As of the 28th of November, Ironwood Pharmaceuticals retains the Market Risk Adjusted Performance of (0.14), risk adjusted performance of (0.05), and Standard Deviation of 4.38. Ironwood Pharmaceuticals technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Ironwood Pharmaceuticals information ratio and skewness to decide if Ironwood Pharmaceuticals is priced fairly, providing market reflects its last-minute price of 3.67 per share. Given that Ironwood Pharmaceuticals has information ratio of (0.11), we strongly advise you to confirm Ironwood Pharmaceuticals's regular market performance to make sure the company can sustain itself at a future point.Ironwood Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ironwood Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ironwood Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Ironwood Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Ironwood Pharmaceuticals' Outstanding Corporate Bonds
Ironwood Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Ironwood Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Ironwood bonds can be classified according to their maturity, which is the date when Ironwood Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| US46333XAH17 Corp BondUS46333XAH17 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Understand Ironwood Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Ironwood Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.05) | |||
| Market Risk Adjusted Performance | (0.14) | |||
| Mean Deviation | 3.41 | |||
| Coefficient Of Variation | (1,280) | |||
| Standard Deviation | 4.38 | |||
| Variance | 19.19 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.63) | |||
| Total Risk Alpha | (1.01) | |||
| Treynor Ratio | (0.15) | |||
| Maximum Drawdown | 20.41 | |||
| Value At Risk | (7.54) | |||
| Potential Upside | 6.62 | |||
| Skewness | 0.1503 | |||
| Kurtosis | 0.3377 |
| Risk Adjusted Performance | (0.05) | |||
| Market Risk Adjusted Performance | (0.14) | |||
| Mean Deviation | 3.41 | |||
| Coefficient Of Variation | (1,280) | |||
| Standard Deviation | 4.38 | |||
| Variance | 19.19 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.63) | |||
| Total Risk Alpha | (1.01) | |||
| Treynor Ratio | (0.15) | |||
| Maximum Drawdown | 20.41 | |||
| Value At Risk | (7.54) | |||
| Potential Upside | 6.62 | |||
| Skewness | 0.1503 | |||
| Kurtosis | 0.3377 |
Consider Ironwood Pharmaceuticals' intraday indicators
Ironwood Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Ironwood Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Ironwood Pharmaceuticals Corporate Filings
F4 | 20th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
| 13th of November 2024 Other Reports | ViewVerify | |
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Ironwood Stock media impact
Far too much social signal, news, headlines, and media speculation about Ironwood Pharmaceuticals that are available to investors today. That information is available publicly through Ironwood media outlets and privately through word of mouth or via Ironwood internal channels. However, regardless of the origin, that massive amount of Ironwood data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Ironwood Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Ironwood Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Ironwood Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Ironwood Pharmaceuticals alpha.
Ironwood Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Ironwood Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Ironwood Pharmaceuticals Corporate Management
| Thomas McCourt | Chief Commercial Officer and Sr. VP of Marketing and Sales | Profile | |
| Jana Noeldeke | Basel Leader | Profile | |
| Ronald Silver | Corporate Officer | Profile | |
| Marcel Moulaison | Vice Operations | Profile | |
| Beth Calitri | Head Relations | Profile | |
| Sravan Emany | Principal VP | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ironwood Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ironwood Pharmaceuticals. If investors know Ironwood will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ironwood Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.77) | Earnings Share (0.01) | Revenue Per Share 2.393 | Quarterly Revenue Growth (0.20) | Return On Assets 0.1305 |
The market value of Ironwood Pharmaceuticals is measured differently than its book value, which is the value of Ironwood that is recorded on the company's balance sheet. Investors also form their own opinion of Ironwood Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ironwood Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ironwood Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ironwood Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Ironwood Pharmaceuticals' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Ironwood Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ironwood Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.